drugset
drugset / Trial / NCT03704428

Safety, Tolerability and PK of SHR1314 in axSpA

NCT03704428 ↗

Phase 1 Completed 45 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the safety, Tolerability and Pharmacokinetics (PK) of SHR1314 with axial spondyloarthritis.

Timeline

Start
2018-04-19
Primary completion
2020-01-14
Completion
2020-01-14

Drugs

EvaluationDrugModalityDoseRoute
Subject vunakizumab Protein / enzyme biologic — Subcutaneous

Indications

spondyloarthropathy